Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Operating Leases (2019 - 2025)

Historic Operating Leases for CytomX Therapeutics (CTMX) over the last 7 years, with Q2 2025 value amounting to $1.4 million.

  • CytomX Therapeutics' Operating Leases fell 7905.59% to $1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year decrease of 7905.59%. This contributed to the annual value of $4.2 million for FY2024, which is 5482.15% down from last year.
  • CytomX Therapeutics' Operating Leases amounted to $1.4 million in Q2 2025, which was down 7905.59% from $2.9 million recorded in Q1 2025.
  • In the past 5 years, CytomX Therapeutics' Operating Leases registered a high of $20.8 million during Q1 2021, and its lowest value of $1.4 million during Q2 2025.
  • For the 5-year period, CytomX Therapeutics' Operating Leases averaged around $11.9 million, with its median value being $12.3 million (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 1368.18% in 2021, then crashed by 7905.59% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Operating Leases stood at $18.1 million in 2021, then dropped by 22.6% to $14.0 million in 2022, then tumbled by 32.84% to $9.4 million in 2023, then tumbled by 54.82% to $4.2 million in 2024, then crashed by 65.99% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q2 2025, $2.9 million for Q1 2025, and $4.2 million during Q4 2024.